Related Experiment Video

Updated: May 5, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

29.7K

Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis

C Takeuchi1, K Ota, Y Ono

  • 1Support Center for Female Medical Scientists; Department of Neurology, Tokyo Women's Medical University, School of Medicine; Tokyo, Japan. - chisentakeuchi@gmail.com.

The Neuroradiology Journal
|December 5, 2013
PubMed

Insights

Interferon beta-1b (IFNβ-1b) treatment may improve axonal function in multiple sclerosis (MS) patients. A study found increased N-acetylaspartate (NAA) to creatine (Cr) ratios in normal-appearing white matter (NAWM) after 24 months of IFNβ-1b treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Radiology

Background:

  • Multiple sclerosis (MS) disability progression is linked to axonal damage in normal-appearing white matter (NAWM).
  • Interferon beta (IFNβ) treatment reduces MS exacerbations and new inflammatory lesions.
  • The impact of IFNβ on axonal damage in MS remains unclear.

Purpose of the Study:

  • To investigate the effect of IFNβ-1b treatment on axonal function in MS patients.
  • To compare axonal function between treated and untreated MS patients using MR spectroscopy (MRS).

Main Methods:

  • Localized single-voxel proton MR spectroscopy (MRS) was used.
  • MRS was performed on 8 MS patients receiving IFNβ-1b and 11 untreated MS patients.
  • Measurements were taken before treatment and at 24 months post-treatment initiation, analyzing N-acetylaspartate (NAA), choline-containing compounds (Cho), and creatine (Cr) ratios.

Main Results:

  • A significant increase in the NAA/Cr ratio was observed in the NAWM of IFNβ-1b treated patients (p=0.028) at 24 months.
  • No significant change in the NAA/Cr ratio was found in the untreated MS patient group.
  • These findings suggest a potential recovery of axonal function with IFNβ-1b treatment.

Conclusions:

  • IFNβ-1b treatment may positively influence axonal function in the NAWM of MS patients.
  • This study provides evidence for a neuroprotective effect of IFNβ-1b beyond its anti-inflammatory actions.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20